喹唑啉类化合物抗癌活性研究进展

李鹏程, 刘刚, 曹琨, 孙林, 温全武

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (11) : 867-874.

PDF(2097 KB)
中国药学杂志
PDF(2097 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (11) : 867-874. DOI: 10.11669/cpj.2016.11.002
综述

喹唑啉类化合物抗癌活性研究进展

  • 李鹏程, 刘刚*, 曹琨, 孙林, 温全武
作者信息 +

Research Progress in Quinazoline Derivatives with Anticancer Activity

  • LI Peng-cheng, LIU Gang*, CAO Kun, SUN Lin, WEN Quan-wu
Author information +
文章历史 +

摘要

喹唑啉环是一种优势骨架结构,可与多种生物大分子结合,产生不同的生物活性,特别是喹唑啉类化合物在抗肿瘤药物研究领域表现尤为突出。通过查阅国内外相关文献,综述近5年来具有抗癌活性的喹唑啉类化合物的国内外研究进展,按照不同喹唑啉环类型分为5类, 分别介绍了各类含喹唑啉环化合物的抗癌生物活性,以便更好地利用现有条件设计合成出活性更好选择性更高的抗癌药物。

Abstract

Quinazoline ring, as a key skeleton structure, can produce a variety of biological activities after combining with multi-kinds of biological macromolecules. Quinazoline compounds have played particularly important roles in the discovery of anticancer drugs. The progress in quinazoline derivatives with anticancer activity was reviewed in this paper. Quinazoline compounds were classified into five types according to different substituent groups. The bioactivities of substituent groups containing quinazoline ring were discussed. And the development trend as well as the prospect of quinazoline derivatives with anticancer activity is summarized.

关键词

喹唑啉 / 喹唑啉酮 / 抗癌活性 / 生物活性

Key words

quinazoline / quinazolinone / anticancer activity / biological activity

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
李鹏程, 刘刚, 曹琨, 孙林, 温全武. 喹唑啉类化合物抗癌活性研究进展[J]. 中国药学杂志, 2016, 51(11): 867-874 https://doi.org/10.11669/cpj.2016.11.002
LI Peng-cheng, LIU Gang, CAO Kun, SUN Lin, WEN Quan-wu. Research Progress in Quinazoline Derivatives with Anticancer Activity[J]. Chinese Pharmaceutical Journal, 2016, 51(11): 867-874 https://doi.org/10.11669/cpj.2016.11.002
中图分类号： R979.1    R914   

参考文献

[1] MCLAUGHLIN N P, EVANS P. Dihydroxylation of vinyl sulfones: stereoselective synthesis of (+)- and (-)-febrifugine and halofuginone [J]. J Org Chem, 2010, 75(2): 518-521.
[2] MANJULA S N, BHARAT E N, DIVYA B. Medicinal and biological significance of quinazoline: a highly important scaffold for drug discovery: a review [J]. Int J Pharm Bio Sci, 2011, 2(1): 780-809.
[3] YANG S H, KHADKA D B, CHO S H, et al. Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors [J]. Bioorg Med Chem, 2011, 19(12): 968-977.
[4] LIU D, LUAN T, YUAN Y, et al. Advance in research for afatinib and its analogues, the multi-target tyrosine kinase inhibitor [J]. Chin Pharm J (中国药学杂志), 2014, 49(24): 2145-2149.
[5] KHAN I, IBRAR A, AHMED W, et al. Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: the advances continue [J]. Eur J Med Chem, 2015, 90(1): 124-169.
[6] AL-OMARY F A M, HASSAN G S, EL-MESSERY S M, et al. Substituted thiazoles V. Synthesis and antitumor activity of novel thiazolo[2,3-b] quinazoline and pyrido[4,3-d] thiazolo[3,2-a]pyrimidine analogues [J]. Eur J Med Chem, 2012, 47(1): 65-72.
[7] HU S J, XIE G J, ZHANG D X, et al. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors [J]. Bioorg Med Chem Lett, 2012, 22(19): 6301-6305.
[8] CHEN X F, DU Y G, SUN H L, et al. Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs [J]. Bioorg Med Chem Lett, 2014, 24(3): 884-887.
[9] AL-OMARY F A M, HASSAN G S, EL-MESSERY S M, et al. Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones [J]. Eur J Med Chem, 2013, 63(1): 33-45.
[10] AL-RASHOOD S T, HASSAN G S, EL-MESSERY S M, et al. Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolylthio and 4-methylthiazolylthio) quinazolin-4-ones as a new class of DHFR inhibitors [J]. Bioorg Med Chem Lett, 2014, 24(18): 4557-4567.
[11] MULAKAYALA N, KANDAGATLA B, ISMAIL, et al. InCl3-catalysed synthesis of 2-aryl quinazolin-4(3H)-ones and 5-arylpyrazolo[4,3-d]pyrimidin-7(6H)-ones and their evaluation as potential anticancer agents [J]. Bioorg Med Chem Lett, 2012, 22(15): 5063-5066.
[12] ALANAZI A M, ABDEL-AZIZ A A M, AL-SUWAIDAN I A, et al. Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents [J]. Eur J Med Chem, 2014, 79(2): 446-454.
[13] YAO H P, ZHU Z X, JI M, et al. Design, synthesis and biological evaluation of novel para-substituted 1-benzyl-quinazoline-2,4(1H,3H)-diones as human PARP-1 inhibitors [J]. Acta Pharm Sin (药学学报), 2014, 49(4): 497-503.
[14] ABBAS S E, BARSOUM F F, GEORGEY H H, et al. Synthesis and antitumor activity of certain 2,3,6-trisubstituted quinazolin-4(3H)-one derivatives [J]. Bull Fac Pharm (Cairo Univ), 2013, 51(2): 273-282.
[15] WENGLOWSKY S, REN L, GRINA J, et al. Highly potent and selective 3-N-methylquinazoline- 4(3H)-one based inhibitors of B-RafV600E kinase [J]. Bioorg Med Chem Lett, 2014, 24(8): 1923-1927.
[16] HAO Y Z. Vandetanib—the first new drug in the treatment of medullary thyroid carcinoma [J]. Chin Pharm J (中国药学杂志), 2013, 48(14): 1229-1230.
[17] CHEN R H, YE L B, YUAN P. Improvement of the synthesis of gefitinib [J]. Chin Pharm J (中国药学杂志), 2012, 47(13): 1084-1087.
[18] MARVANIA B, LEE P C, CHANIYARA R, et al. Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates [J]. Bioorg Med Chem, 2011, 19(6): 1987-1998.
[19] LI H Q, LI D D, LU X, et al. Design and synthesis of 4,6-substituted-(diaphenylamino) quinazolines as potent EGFR inhibitors with antitumor activity [J]. Bioorg Med Chem, 2012, 20(1): 317-323.
[20] LI D D, FANG F, LI J R, et al. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors [J]. Bioorg Med Chem Lett, 2012, 22(18): 5870-5875.
[21] ZHANG L, FAN C W, GUO Z R, et al. Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer [J]. Eur J Med Chem, 2013, 69(3): 833-841.
[22] ZHAO F, LIN Z H, WANG F, et al. Four-membered heterocycles-containing 4-anilino- quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors [J]. Bioorg Med Chem Lett, 2013, 23(19): 5385-5388.
[23] LI S L, WANG X, HE Y, et al. Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer [J]. Eur J Med Chem, 2013, 67(1): 293-301.
[24] LIM C J, OH K S, HA J D, et al. 4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors [J]. Bioorg Med Chem Lett, 2014, 24(17): 4080-4083.
[25] CHENG W Y, YUAN Y T, QIU N, et al. Identification of novel 4-anilino quinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia [J]. Bioorg Med Chem, 2014, 22(24): 6796-6805.
[26] CHENG W Y, ZHU S J, MA X D, et al. Design, synthesis and biological evaluation of 6-(nitroimidazole-1Halkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia [J]. Bioorg Med Chem, 2015, 89(3): 826-834.
[27] JUVALE K, GALLUS J, WIESE M. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2) [J]. Bioorg Med Chem, 2013, 21(24): 7858-7873.
[28] WANG Y K, JIN J, ZHU L N, et al. Synthesis and antitumor activity of novel 2-(1-substituted-piperidin-4-ylamino)quinazolines as antitumor agents [J]. Acta Pharm Sin (药学学报), 2012, 47(9): 1164-1178.
[29] PAUL K, SHARMA A, LUXAMI V, et al. Synthesis and in vitro antitumor evaluation of primary amine substituted quinazoline linked benzimidazole [J]. Bioorg Med Chem Lett, 2014, 24(2): 624-629.
[30] BARBOSA M L C, LIMA L M, TESCH R, et al. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors [J]. Eur J Med Chem, 2014, 71(1): 1-14.
[31] HUANG K H, BARTA T E, RICE J W, et al. Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90 [J]. Bioorg Med Chem Lett, 2012, 22(7): 2550-2554.
[32] JIANG N, ZHAI X, ZHAO Y F, et al. Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents [J]. Eur J Med Chem, 2012, 54(2): 534-541.
[33] ZHANG Y, HUANG Y J, XIANG H M, et al. Synthesis and anticancer activities of 4-(4-substituted piperazin)-5,6,7-trialkoxy quinazoline derivatives [J]. Eur J Med Chem, 2014, 78(1): 23-34.
[34] SHAO T, WANG J, CHEN J G, et al. Discovery of 2-methoxy-3-phenylsulfonamino- 5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere [J]. Eur J Med Chem, 2014, 75(1): 96-105.
[35] MORENO E, PLANO D, LAMBERTO I, et al. Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: synthesis and study of their potential cytotoxic activity in vitro [J]. Eur J Med Chem, 2012, 47(1): 283-298.
[36] LUO H, YANG S J, CAI Y Q, et al. Synthesis and biological evaluation of novel 6-chloro-quinazolin derivatives as potential antitumor agents [J]. Eur J Med Chem, 2014, 84(3): 746-752.
[37] LIU G, LIU C P, XU S G. Diquinazoline diselenide compound as well as preparation method and bioactivity thereof: China, 102627614 [P]. 20120808.
[38] HUANG Y J, LIU G, HU X M, et al. A potential anticancer agent 1, 2-di(quinazolin-4-yl)diselane [J]. Lett Drug Des Discov, 2014, 11(2): 731-735.

基金

山东省自然科学基金资助项目(ZR2013BM006)
PDF(2097 KB)

118

Accesses

0

Citation

Detail
段落导航
相关文章

/

〈 〉